Animal-health-products-for-vets1
KELACEFforcowspigs
item4
Phoenixbirdshade

'Click' below Quick Select

Prescription Products

KELACEF

Suspension for injection for cattle and pigs

Ceftiofur 50 mg/mL (as hydrochloride)

  • RTU formulation with excellent syringeability
  • Short withdrawal time for meat
  • No withdrawal for milk

Advantages

RESTRICTED VETERINARY MEDICINE KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY

Active substance:
50 mg Ceftiofur (as hydrochloride)
White to off-white, beige suspension.

Use during pregnancy and lactation
The reproductive safety of ceftiofur has not been specifically investigated in pregnant sows or cows.

Interactions
None known.

Overdose
T
he low toxicity of ceftiofur has been demonstrated in pigs using ceftiofur sodium at doses in excess of 8 times the recommended daily dose of ceftiofur intramuscularly administered for 15 consecutive days.

In cattle, no signs of systemic toxicity have been observed following substantial parenteral overdosages.

Incompatibilities
None known.

INDICATIONS

Infections associated with bacteria sensitive to ceftiofur:

Pigs:

For the treatment of bacterial respiratory disease associated with Pasteurella multocida, Actinobacillus pleuropneumoniae and Streptococcus suis.

Cattle:

For the treatment of bacterial respiratory disease associated with Pasteurella haemolytica (Mannheimia spp.), Pasteurella multocida and Haemophilus somnus.

For the treatment of acute interdigital necrobacillosis (panaritium, foot rot), associated with Fusobacterium necrophorum and Bacteroides melaninogenicus (Porphyromonas asaccharolytica ).

For treatment of the bacterial component of acute post-partum (puerperal) metritis within 10 days after calving associated with bacterial organisms sensitive to ceftiofur.

The indication is restricted to cases where treatment with another antimicrobial has failed.

SPECIAL WARNING(S)

Use of KELACEF 50 mg/ml suspension for injection for pigs and cattle may constitute a risk to public health due to spread of antimicrobial resistance.

KELACEF 50 mg/ml suspension for injection for pigs and cattle should be reserved for the treatment of clinical conditions which have responded national and regional antimicrobial policies should be taken into account when the product is used. Increased use, including use of the product deviating from the instructions given, may increase the prevalence of resistance. Whenever possible, KELACEF 50 mg/ml suspension for injection for pigs and cattle should only be used based on susceptibility testing.

DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION

Intramuscular injections should be made by directing the needle of suitable gauge and length into the anterior half of the neck. Before injecting the solution, pull back gently on the plunger. If blood appears in the syringe, a blood vessel has been entered; withdraw the needle and select a different site. No more than 10mL solution should be injected per site.

Pigs:

3 mg ceftiofur /kg bw/day for 3 days via intramuscular route, i.e. 1 ml/16 kg bw at each injection. If no improvement is seen within 3-5 days, re-determine the diagnosis.

Cattle:

Respiratory disease: 1 mg ceftiofur /kg bw/day for 3 days by subcutaneous injection, i.e. 2 ml/100 kg bw at each injection. Additional treatments should be

Acute interdigital necrobacillosis (foot rot): 1 mg/kg bw/day for 3 days by subcutaneous injection, i.e. 2 ml/100 kg bw at each injection.

Acute post-partum metritis within 10 days after calving: 2.2 mg/kg bw/day at 24 hour intervals for 5 consecutive days by subcutaneous injection, i.e. 4.4 ml/100 kg bw at each injection.

Subsequent injections must be given at different sites.
In case of acute post-partum metritis, additional supportive therapy might be required in some cases.

WITHHOLDING PERIOD

It is an offence for users of this product to cause residues exceeding the relevant MRL in the NZ (Maximum Residues Limits of Agricultural Compounds) Food Standards.

Meat:

Cattle and pigs producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 2 days of cessation of the last treatment.

Milk:

No milk withholding period is required when the product is used according to label directions. Use of doses in excess of those recommended on the label may result in illegal drug residues in edible tissues.

Not for use in bobby calves.ADVERSE REACTIONS

Hypersensitivity reactions unrelated to dose can occur. Allergic reactions (e.g. skin reactions, anaphylaxia) may occasionally occur.

Pigs: Mild reactions at the injection site, such as discoloration of the fascia or fat, have been observed in some animals for up to 20 days after injection.

Cattle: Mild inflammatory reactions at the injection site, such as tissue edema and discoloration of the subcutaneous tissue and/or fascial surface of the muscle may be observed. Clinical resolution is reached in most animals by 10 days after injection although slight tissue discoloration may persist for 28 days or more.

CONTRAINDICATIONS

Do not administer to an animal previously found to be hypersensitive to ceftiofur and other ß -lactam antibiotics. Do not inject intravenously.

Do not use in poultry (including eggs) due to risk of spread of antimicrobial resistance to humans.

SPECIAL PRECAUTIONS FOR USE IN ANIMALS

Shake the bottle well before use to bring the product back into suspension.
In case of the occurrence of allergic reaction the treatment should be withdrawn.
Do not use as prophylaxis in case of retained placenta.

SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE PRODUCT

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious. Do not handle this product if you know you are sensitized, or if you have been advised not to work with such preparations. If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.

SPECIAL STORAGE PRECAUTIONS

Keep out of the reach and sight of children.
Do not refrigerate or freeze.
Protect from light.
Store below 25°C.
Do not use after the expiry date stated on the label.
Shelf life after first opening the container: 28 days.

When the container is broached (opened) for the first time, the date on which any product remaining in the container should be discarded should be worked out. This discard date should be written in the space provided on the label.

To be supplied only on veterinary prescription

Registration
Registered pursuant to the ACVM Act 1997, No. A10848.
See www.foodsafety.govt.nz for registration conditions

Registered to:
 

KELA N.V.,
St.Lenaartseweg 48, 2320 Hoogstraten, Belgium,
info@kela.be, + 32 3 340 04 11, manufactured in Belgium.

NZ Agent & Distributor:
 

Phoenix Pharm Distributors Ltd
PO Box 31363, Mairangi Bay, Auckland

homepage150
item1a1a
item1a1
PhoenixPharmlogoRGB
Back
KELACEFsuspensionforinjection
METRICYCLINflyerMay2014

Download brochure